findmyKOL

Faith Davies, MD

Enriched profile

Professor, Department of Medicine, NYU Grossman School of Medicine; Director, Clinical Myeloma Program, Perlmutter Cancer Center; Inaugural Director, Center for Blood Cancers, Perlmutter Cancer Center · NYU Langone Health

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyHematologyFocusHematology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2026–2026

Faith Davies is Professor, Department of Medicine, NYU Grossman School of Medicine; Director, Clinical Myeloma Program, Perlmutter Cancer Center; Inaugural Director, Center for Blood Cancers, Perlmutter Cancer Center at NYU Langone Health. OpenAlex indexes 1,151 publications with 40,591 citations (h-index 99); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Faith E. Davies, MD, is Professor, Department of Medicine, NYU Grossman School of Medicine at NYU Langone Health / Perlmutter Cancer Center. The public record shows 1,151 publications with 40,591 citations (h-index 99), centered on Hematology. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 14 companies, 1 NIH-funded awards (2026–2026).

  • Most recent indexed publication: 2026 · Blood cancer discovery
  • Top research focus: Hematology
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 14 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma3 trials

Research focus

OpenAlex concept fingerprint
Hematology

Drugs & molecules

across trials, industry payments and publications
Revlimidgeneric · LenalidomideClinical trialsIndustry payments1Publications1Darzalexgeneric · DaratumumabClinical trialsIndustry payments20PublicationsCarvyktigeneric · Ciltacabtagene autoleucelClinical trialsIndustry payments15Publications

Works with

trial sponsors and companies reporting payments
Janssen Global Services, LLCClinical trialsIndustry payments20GlaxoSmithKline, LLC.Clinical trialsIndustry payments11Takeda Pharmaceuticals U.S.A., Inc.Clinical trialsIndustry payments11

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,151publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

40,591citations

Total citations across indexed works.

99h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
14companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2026–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    53.7%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor53.7%
    Acyclovir100%
    Part D11 patients
  • Nervous system

    15.9%
    Opioid Agonist15.9%
    Oxycodone Hcl100%
    Part D<11 patients
  • Cancer & immunology

    15.9%
    Thalidomide Analog15.9%
    Revlimid100%
    Part D<11 patients
1 more therapeutic area behind the reveal.Reveal →
Where care is delivered (Part B)17.1% facility · 82.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 20262026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/faith-davies-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • X / Twitter

    x.com/FaithEDavies1

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/posts/nyulangonehealth_dr-faith-davies-a-nationally-renowned-hematology-activity-6922544883979186176-OgH_

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    healthtree.org/myeloma/community/podcasts/essential-research-for-myeloma-cures

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org
  • X / Twitter

    x.com/Myeloma_Society/status/1968426613005017237

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    HMWG Steering Committee, American Association for Cancer Research

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org
  • Member

    Membership Committee, International Myeloma Society

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomasociety.org
  • Active member

    American Society of Hematology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org
2 more roles behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Previously Medical Director

    Myeloma Institute, and Professor of Medicine, University of Arkansas for Medical Sciences

    2019
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com
  • Member

    Hematologic Malignancies Working Group (HMWG) Steering Committee, American Association for Cancer Research (AACR)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.